Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

Core Insights - Viking Therapeutics, Inc. is set to release its financial results for Q4 and year-end 2025 on February 11, 2026, after market close [1] - A conference call will be held on the same day at 4:30 p.m. Eastern Time to discuss these results and provide corporate updates [2] Company Overview - Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders [3] - The company is advancing several clinical programs, including VK2735, a dual agonist for GLP-1 and GIP receptors, currently in Phase 3 trials for obesity [3] - VK2809, another key program, is an orally available small molecule for treating lipid and metabolic disorders, having met primary and secondary endpoints in a Phase 2b study for NASH [3] - The company is also developing VK0214 for X-ALD, which has shown safety and efficacy in reducing VLCFAs in a Phase 1b trial [3]